secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-08-06T21:30:33+00:00
Accession:  0001193125-26-338480
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Executive Chair Barbara Weber departs effective August 3, 2026
--------------------------------------------------------------------------------

- Dr. Weber's employment ended Aug 3, 2026; she resigned from all officer and board positions.
- Resignation not due to any disagreement with the Company's operations, practices or policies.
- Severance includes base salary through Dec 31, 2026, COBRA reimbursement, and 12-month vesting acceleration.
- Vested stock option exercise period extended to Aug 3, 2027; pro-rata 2026 annual incentive offered.
- Benefits contingent on execution of a Separation Agreement; no successor named.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526338480/0001193125-26-338480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526338480/d41277d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer